tradingkey.logo
๎™
๎™ผ
tradingkey.logo
๎™

ARS Pharmaceuticals Inc

SPRY
๎˜น
์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ
8.070USD
-0.490-5.72%
์ข…๊ฐ€ย 03/27, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
266.85M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™
Intraday
1m
30m
1h
D
W
M
D

์˜ค๋Š˜

-5.72%

5์ผ

-1.22%

1๊ฐœ์›”

-13.04%

6๊ฐœ์›”

-16.98%

์˜ฌํ•ด ํ˜„์žฌ๊นŒ์ง€

-30.73%

1๋…„

-35.39%

์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ

TradingKey ARS Pharmaceuticals Inc ์ฃผ์‹ ์ ์ˆ˜๎˜

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2026-03-27

์ฃผ์š” ์ธ์‚ฌ์ดํŠธ

ARS Pharmaceuticals Inc์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ๋น„๊ต์  ์•ˆ์ •์  ์ƒํƒœ์ด๋ฉฐ, ESG ๊ณต์‹œ๋Š” ์—…๊ณ„๋ฅผ ์„ ๋„ํ•˜๋Š” ์ˆ˜์ค€์ž…๋‹ˆ๋‹ค.์„ฑ์žฅ ์ž ์žฌ๋ ฅ์€ ๋†’์Šต๋‹ˆ๋‹ค.๊ธฐ์—…์˜ ๋ฐธ๋ฅ˜์—์ด์…˜์€ ์ ์ •ํ•˜๊ฒŒ ํ‰๊ฐ€๋œ ๊ฒƒ์œผ๋กœ ๊ฐ„์ฃผ๋˜๋ฉฐ, ์ƒ๋ช…๊ณตํ•™ ๋ฐ ์˜๋ฃŒ ์—ฐ๊ตฌ ์‚ฐ์—…์—์„œ 391๊ฐœ ์ค‘ 49์œ„ ๋žญํ‚น.๊ธฐ๊ด€ ๋ณด์œ  ๋น„์œจ์€ ๋งค์šฐ ๋†’์€.์ง€๋‚œ ํ•œ ๋‹ฌ ๋™์•ˆ ์—ฌ๋Ÿฌ ์• ๋„๋ฆฌ์ŠคํŠธ๊ฐ€ ํ•ด๋‹น ๊ธฐ์—…์„ ๊ฐ•๋ ฅ ๋งค์ˆ˜(์œผ)๋กœ ํ‰๊ฐ€ํ–ˆ์œผ๋ฉฐ, ์ตœ๊ณ  ๋ชฉํ‘œ ๊ฐ€๊ฒฉ์€ 26.67์ž…๋‹ˆ๋‹ค.์ค‘๊ธฐ์ ์œผ๋กœ ์ฃผ๊ฐ€๋Š” ํ•˜๋ฝ ์ถ”์„ธ์ผ ๊ฒƒ์œผ๋กœ ์˜ˆ์ƒ๋ฉ๋‹ˆ๋‹ค.์ง€๋‚œ ํ•œ ๋‹ฌ๊ฐ„ ์ฃผ์‹ ์‹œ์žฅ์—์„œ ๋ถ€์ง„ํ•œ ์„ฑ๊ณผ๋ฅผ ๊ฑฐ๋‘์—ˆ์ง€๋งŒ, ๊ธฐ์—…์˜ ํŽ€๋”๋ฉ˜ํ„ธ๊ณผ ๊ธฐ์ˆ ์  ์ง€ํ‘œ๋Š” ํƒ„ํƒ„ํ•ฉ๋‹ˆ๋‹ค.์ฃผ๊ฐ€๋Š” ์ง€์ง€์„ ๊ณผ ์ €ํ•ญ์„  ์‚ฌ์ด์—์„œ ํšก๋ณดํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ๋ฒ”์œ„ ๋งค๋งค ๊ธฐ๋ฐ˜์˜ ์Šค์œ™ ํŠธ๋ ˆ์ด๋”ฉ์— ์ ํ•ฉํ•œ ์ƒํ™ฉ์ž…๋‹ˆ๋‹ค.

ARS Pharmaceuticals Inc ์ ์ˆ˜๎˜ฐ๎˜ฐ

๊ด€๋ จ ์ •๋ณด

์‚ฐ์—… ์ˆœ์œ„
49 / 391
์ „์ฒด ์ˆœ์œ„
152 / 4542
์‚ฐ์—…
์ƒ๋ช…๊ณตํ•™ ๋ฐ ์˜๋ฃŒ ์—ฐ๊ตฌ

์ €ํ•ญ์„  & ์ง€์ง€์„ 

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

๋ ˆ์ด๋” ์ฐจํŠธ

ํ˜„์žฌ ๊ฐ€๊ฒฉ
๊ณผ๊ฑฐ

๋ฏธ๋””์–ด ๋ณด๋„

์ตœ๊ทผ 24 ์‹œ๊ฐ„
๋ณด๋„ ์ˆ˜์ค€

๋งค์šฐ ๋‚ฎ์€
๋งค์šฐ ๋†’์€
์ค‘๋ฆฝ

ARS Pharmaceuticals Inc ์ฃผ์š” ๋‚ด์šฉ

๊ฐ•์ ์œ„ํ—˜ ์š”์†Œ
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
๋†’์€ ์„ฑ์žฅ
ํšŒ์‚ฌ์˜ ๋งค์ถœ์€ ์ง€๋‚œ 3๋…„๊ฐ„ ๊พธ์ค€ํžˆ ์„ฑ์žฅํ•ด์™”์œผ๋ฉฐ, ์—ฐํ‰๊ท  280826.67%์˜ ์ฆ๊ฐ€์œจ์„ ๊ธฐ๋กํ–ˆ์Šต๋‹ˆ๋‹ค.
์„ฑ์žฅ ์ค‘
ํšŒ์‚ฌ๋Š” ์„ฑ์žฅ ๋‹จ๊ณ„์— ์žˆ์œผ๋ฉฐ, ์ตœ์‹  ์—ฐ๊ฐ„ ์ˆ˜์ต์€ ๋ฏธํ™” 84.28M์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค.
๊ณ ์ˆ˜์ต ์„ฑ์žฅ
ํšŒ์‚ฌ์˜ ์ˆœ์ด์ต์€ ์—…๊ณ„ ์„ ๋‘๋ฅผ ๋‹ฌ๋ฆฌ๊ณ  ์žˆ์œผ๋ฉฐ, ์ตœ๊ทผ ์—ฐ๊ฐ„ ์ˆœ์ด์ต์€ ๋ฏธํ™” 84.28M์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค.
์†์‹ค ์ „ํ™˜
ํšŒ์‚ฌ์˜ ์‹ค์ ์ด ์ ์ž๋กœ ์ „ํ™˜๋˜์–ด, ์ตœ๊ทผ ์—ฐ๊ฐ„ ์†์‹ค์€ ๋ฏธํ™” ๋‹ฌ๋Ÿฌ์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค
๊ณผ๋Œ€ ํ‰๊ฐ€๋œ
ํšŒ์‚ฌ์˜ ์ตœ์‹  PE์€ -4.64๋กœ, ์ตœ๊ทผ 3๋…„ ๊ธฐ์ค€ ๋†’์€ ๋ฐฑ๋ถ„์œ„ ๋ฒ”์œ„์— ์†ํ•ฉ๋‹ˆ๋‹ค.
๊ธฐ๊ด€ ๋งค๋„
์ตœ์‹  ๊ธฐ๊ด€ ๋ณด์œ  ์ฃผ์‹ ์ˆ˜๋Š” 88.21M์ฃผ์ด๋ฉฐ, ์ „ ๋ถ„๊ธฐ ๋Œ€๋น„ 10.51% ๊ฐ์†Œํ–ˆ์Šต๋‹ˆ๋‹ค.
๋” ๋ฑ…๊ฐ€๋“œ๊ฐ€ ๋ณด์œ 
์Šคํƒ€ ํˆฌ์ž์ž ๋” ๋ฑ…๊ฐ€๋“œ์ด(๊ฐ€) ์ด ์ฃผ์‹ 3.50M์ฃผ๋ฅผ ๋ณด์œ ํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.
์‹œ์žฅ ํ™œ๋™ ์ฆ๊ฐ€
ํšŒ์‚ฌ๋Š” ํˆฌ์ž์ž๋“ค์˜ ๊ด€์‹ฌ์ด ๋†’์•„์ ธ, ์ตœ๊ทผ 20์ผ๊ฐ„ ํšŒ์ „์œจ์ด 1.06์ž…๋‹ˆ๋‹ค.

๋ถ„์„๊ฐ€ ๋ชฉํ‘œ๊ฐ€

6 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๊ฐ•๋ ฅ ๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
26.667
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
+211.53%
์ƒ์Šน ์—ฌ๋ ฅ
๋ฉด์ฑ… ์กฐํ•ญ: ์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€ ๋ฐ ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” ์ •๋ณด ์ œ๊ณต์„ ์œ„ํ•œ ๋ชฉ์ ์œผ๋กœ LSEG์—์„œ ์ œ๊ณต๋˜๋ฉฐ, ํˆฌ์ž ์กฐ์–ธ์œผ๋กœ ๊ฐ„์ฃผ๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.

ARS Pharmaceuticals Inc ๋‰ด์Šค

๋” ๋งŽ์€ ๋‰ด์Šค๊ฐ€ ๊ณง ์—…๋ฐ์ดํŠธ๋ฉ๋‹ˆ๋‹ค. ๊ณ„์† ์ง€์ผœ๋ด ์ฃผ์„ธ์š”โ€ฆ

์žฌ๋ฌด ์ง€ํ‘œ๎˜

EPS

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ด ์ˆ˜์ต

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

ARS Pharmaceuticals Inc ์ •๋ณด๎˜

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
์ข…๋ชฉ ์ฝ”๋“œ SPRY
ํšŒ์‚ฌARS Pharmaceuticals Inc
CEOLowenthal (Richard E)
์›น์‚ฌ์ดํŠธhttps://ars-pharma.com/
KeyAI
๎™